BioSpace News Archive

Drug Development

Mirati’s KRAS Inhibitor Demonstrates Encouraging Clinical Profile in Latest Data Drop (Updated)

Mirati’s adagrasib demonstrated a solid safety profile in new data released Monday. Despite this, the company’s stock fell 8% in after-hours trading.

December 6, 2022
·
3 min read
·
Mark Terry
Drug Development

Gossamer’s PAH Candidate Meets Primary Endpoint, Stumbles on Secondary Measure

Topline results from the Phase II TORREY study showed Gossamer Bio’s seralutinib met its primary efficacy endpoint in pulmonary arterial hypertension.

December 6, 2022
·
3 min read
·
Tristan Manalac
Business

Entact Bio Draws $81M Financing for Protein Enhancement Platform (Updated)

Entact Bio launched with $81 million Tuesday to advance its protein enhancement platform.

December 6, 2022
·
2 min read
·
Rosemary Scott
Business

MEI Abandons PI3K Inhibitor, 30% of Staff in Strategic Shift

MEI Pharma, Inc. will have a strategic realignment that would see at least 30% of its workforce laid off and a pivot towards two of its earlier clinical-stage assets.

December 6, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Editas’ Latecomer SCD Therapy Shows Promise in Two Patients

Editas Medicine released positive proof of concept data Tuesday morning from the first patients dosed with its experimental CRISPR-based gene therapy for sickle cell disease.

December 6, 2022
·
3 min read
·
Alex Keown
Drug Development

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced new preclinical data showing KIN001’s strong antiviral efficacy against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5.

December 6, 2022
·
3 min read
Business

Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Evaxion Biotech A/S\ announces that the Company has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS for the joint development of a novel cytomegalovirus vaccine candidate.

December 6, 2022
·
7 min read
BioMidwest

AbbVie to Showcase Migraine Portfolio and Pipeline During the 16th European Headache Federation Congress

AbbVie announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation Congress 2022 taking place in Vienna, Austria, December 7-10.

December 6, 2022
·
18 min read
AMO Pharma Announces Completion of Enrollment in REACH-CDM Study in Congenital Myotonic Dystrophy

AMO Pharma Limited announced completion of patient enrollment in the company’s REACH-CDM study of the investigational therapy AMO-02 in treatment of congenital myotonic dystrophy.

December 6, 2022
·
2 min read
Drug Development

The subscription period in AlzeCure Pharma AB’s Rights Issue Begins Today and the CEO has Participated in a Company Presentation and CEO Interview with Erik Penser Bank

AlzeCure Pharma AB announced that the subscription period in the Company’s capital raising begins December 06 and runs until December 20, 2022.

December 6, 2022
·
2 min read